📰 ET Markets 🟢 BULLISH 🕒 30 Oct 2026, 12:27 AM IST

Cash takes centre stage as investors rethink AI spending boom

⚡ Instant Key Takeaways (TL;DR)

🎯

Core Development: Cash takes centre stage as investors rethink AI spending boom

📊

Market & Financial Impact: Investors are increasingly focused on technology companies' cash generation capabilities to fund artificial intelligence investments. Microsoft and Oracle are gaining positive attention from investors, while Alphabet faces challenges due to rising AI costs. Alphabet's spending has surpassed its operating cash flow, raising concerns about its financial sustainability. In contrast, Microsoft's strong cash flow and forecasted growth indicate effective AI investment returns.

💡

Actionable Insight: 🟢 Bullish Trigger: Positive business expansion or earnings beat may attract institutional and retail buying.

Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

KYB and KYC: Quick commerce, the Damani premium and what DMart must deliver – 3rd and concluding part

KYC and KYB: Inside Damani’s DMart, the retail chain for the middle class. And stock for the long term? – Part 2 of 3

Will it be a regulatory nightmare if an exchange lists on its own platform?

📰

Official Publisher Attribution: This report is aggregated from Economic Times. ZeroLive provides live aggregation, automated sentiment synthesis, and exchange disclosure monitoring for retail market participants.

Read Original Full Coverage on Economic Times ↗

⚡

Get Breaking Stock Alerts & Q-Results on Telegram

Real-time 1200x675 image cards and financial filings delivered instantly.

Join @Zerolive_news ↗

Cash takes centre stage as investors rethink AI spending boom

🔥 More Live Market Stories

Wall Street's AI fears slash Google value by $500bn

Kimberly-Clark completes $4.9 billion senior notes offering to support Kenvue deal

Colombia stocks lower at close of trade; COLCAP down 0.64%

Goldman Sachs downgrades Bicara Therapeutics stock rating to sell

BridgeBio Pharma earnings beat by $0.14, revenue topped estimates

Amass Brands updates bylaws to modify quorum requirement for shareholder meetings